Marc Hilmi: The intratumoral heterogeneity of pancreatic ductal adenocarcinoma
Marc Hilmi, Chercheur postdoctoral at Memorial Sloan Kettering Cancer Center, shared a paper he and his colleagues authored on LinkedIn:
“Part of my PhD work has been published in The Journal of Pathology!
In this study, we explored the intratumoral heterogeneity of pancreatic ductal adenocarcinoma (PDAC), a crucial but less understood aspect compared to interpatient variability.
We developed an IHC panel to distinguish between RNA-defined classical and basal-like PDAC subtypes, leading to the identification of key markers, including GATA6, CLDN18, TFF1, MUC16, S100A2, KRT17, and PanBasal, as well as four distinct phenotypic profiles. Importantly, our findings revealed that even a minor basal-like component within a tumor significantly worsens overall survival, emphasizing the clinical impact of intratumoral heterogeneity.
I am incredibly grateful to my PhD supervisors, Rémy Nicolle and Cindy NEUZILLET, for their unwavering support and guidance, and a special thank you to Jerome Cros, whose expertise in pathology was invaluable, I learned so much.
Amazing collaboration with Flore Delecourt, Jerôme RAFFENNE, Taib Abderaouf Bourega, Nelson Dusetti, Juan Iovanna, Yuna Blum, Magali Richard, Anne Couvelard, Matthieu Tihy, Louis de Mestier, Vinciane Rebours.
Diving deep into PDAC phenotyping has been a fascinating journey, and I am excited about the implications of these findings for future cancer research and precision medicine.”
Nelson Dusetti, Head of the Department of Translational Research and Innovative Therapies at CRCM, shared this post , adding:
“Congratulations to the team for this outstanding contribution to advancing pancreatic cancer research. It’s a privilege to be part of it!!
This study stands out by:
– Utilizing advanced tile-based analysis of whole tumor slides, uncovering remarkable intratumoral heterogeneity where classical, basal, and intermediate clusters coexist within the same tumor.
– Identifying a major Intermediate subtype, going beyond the traditional binary classification and shedding light on PDAC’s complexity.
– Highlighting how this heterogeneity and plasticity may contribute to resistance to treatment and poor prognosis, reinforcing the need for more precise therapeutic approaches.
Providing researchers and clinicians with critical tools for refining our understanding of this complex disease.”
Authors: Marc Hilmi et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023